



We are MeOmics

Our Neural Biomarker Platform Will
Transform Mental Health Drug Development

-  **Alasdair Pettigrew**
-  +44 7711 850102
-  alasdair@meomics.tech

WWW.MEOMICS.TECH





— The Time is Right for the MeOmics Vision

There is no existing neuronal cell panel of mental health conditions...

Meaning no data available for AI-based med-tech companies to use, presenting early revenue opportunities for MeOmics

There is no high throughput platform for drug screening for mental health conditions...

Meaning drug developers need to reduce the cost and risk of clinical trials, presenting significant revenue opportunities for MeOmics

— Global Challenge of Mental Health



Mental Health
Illnesses are:
**Half of Top 10
Conditions**





Global Mental
Illness Costs:
**Hundreds of
\$BILLIONS**



High Drug Dev.
Failure Rate:
**Only 1 in 20
Succeed**


— The MeOmics **Value Proposition**

A Neuronal Biomarker
Platform from clinical patients



MeOmics' **Unique IP**

The MeOmics Platform



MeOmics Key Milestones Achieved

Population

- Generate 150 iPSC lines from 50 patient donors
- Stored as MEA-ready master stocks
- Conduct highly parallel MEA assays



+ Pharmacology




Control




Signal Differences Identified




Signal Modification Shown




= Prediction



AI/ML analysis **commencing** to identify patient clusters and match drug to patient




Highly Scalable Business Models



Revenue Growth Projections

MeOomics Revenue & Cost Plan



Competitive Landscape is Evolving



Global Research &
Press Interest e.g.:

The Economist



Early-Stage
Competitors are
Emerging e.g.:


Herophilus



Established Firms
May Pivot e.g.:

**Fujifilm Cellular
Dynamics**

— Significant Business Validation & Traction



Recent Value Inflection Points for MeOmics

Recent Scientific & business Achievements (as of early 2024)

Pipeline from patients to iPSC



- ✓ Recruitment of 50 Schizophrenia Patients
- ✓ Generation of 300 iPSC lines (6 from each of the 50 donors)

Assay-ready cells



- ✓ Generation of iPSC master stocks from all 150 clones
- ✓ Stored as Neural Progenitor Cells, ready for cell assays

Differential Signals Detected and Patent(s) Being Filed



- ✓ Demonstrated electrophysiological signals differentiate patient & non-patient cells
- ✓ Indications of patient stratification differences - signal data AI/ML analysis commencing

Parallelisation of MEA assays



- ✓ Ongoing assay of 28 patients and control iPSC-derived neurons (multi-well format)
- ✓ Testing four novel compounds has shown “normalisation” of schizophrenia signal

Engagement with Initial Customers



- ✓ First commercial proposals submitted to rare disease patient groups
- ✓ Ongoing screening platform discussions with interested drug development companies

— MeOmics - Significant ESG Impact

MeOmics are committed to protecting the environment



Enabling the reduction in animal testing in drug development

MeOmics are committed to good governance



Actively adopting best practice governance processes and policies


MeOmics will deliver significant social impact



Creating high-value jobs and investment in South Wales

The most **profound** MeOmics **social impact** will be the global **transformation** of **mental illnesses**

— How MeOmics Will Use this Pre-Seed Funding



WITH THIS MONEY WE WILL:

- + **Gather more patient samples** – targeting around 150 in total, gathering highly valuable data
- + **Accelerate our process throughput** with robotics and automation
- + Recruit **data analysts** to ramp up **AI data merging, ML and population modelling**
- + **Secure** early **revenues** from medical AI/ML companies
- + Commence preparations to establish our **lab in the Cardiff area**

This capital plus grant funding will provide a runway to the Seed fundraise of £3m in late 2025

Allowing the recruitment of a commercial team to find customers and grow revenues, carrying MeOmics past breakeven and into positive EBITDA

— Introducing Team MeOmics



Alasdair Pettigrew
Chief Executive Officer



Dr Lucy Sykes
Special Advisor
(Chief Scientific Officer)



Professor Adrian Harwood
Chief Technology Officer



Professor Jeremy Hall
Chief Medical Officer



Alicia Campbell
Stem Cell Biologist



Professor James Walters
Special Advisor

Technology commercialisation – business start-up/spin-out expert

Expert in Cell & Molecular Biology

Leading expert in neuronal cell biology and neuropsychopharmacology

Leading expert in psychiatric phenotypes and biomarkers

Extensive experience in upscaling stem cells and process development

Expert in neuropsychiatric genetics and genomics

[Biography Link](#)

[Biography Link](#)

[Biography Link](#)

[Biography Link](#)

[Biography Link](#)

[Biography Link](#)

Supported by a distinguished Scientific Advisory Board

Thank you

MeOmics plan to develop a unique platform for neural biomarker discovery that will transform drug development for mental illness

 Alasdair Pettigrew

 +44 7711 850102

 alasdair@meomics.tech

WWW.MEOMICS.TECH

